27F Stock Chart & Stats
€3.40
€0.00(0.00%)
At close: 4:00 PM EDT
€3.40
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.40 - €849.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.38M
Enterprise Value-€7.10
Total Cash (Recent Filing)€7.23M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.22
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,339,787
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-0.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetEliminating debt reduces interest and refinancing pressure, giving Kala Bio more financial flexibility than in prior years. Positive equity also provides some balance-sheet support, although the relatively small asset base means this cushion remains limited if losses continue.
Exclusive Ophthalmic Testing DistributionThe five-year exclusive agreement gives Kala Bio a defined commercial role in ophthalmic genetic testing without requiring it to manage delivery and administration. The equal profit split and right of first refusal could create longer-term strategic options if the program gains adoption.
Improving Loss LevelA lower TTM loss suggests some progress in reducing operating losses compared with earlier periods. If sustained, improving loss control could extend financial flexibility and support a path toward greater operating efficiency, though the company remains far from profitability.
Bears Say
No Meaningful Revenue BaseNear-zero revenue means Kala Bio currently lacks demonstrated operating scale or recurring sales to fund its business. This leaves future progress dependent on establishing commercial traction, making earnings visibility and the sustainability of the business model weak over the next several quarters.
Persistent Cash BurnContinued cash consumption without a revenue base increases liquidity pressure and makes external financing important to maintain operations. Even though burn improved from 2025, ongoing negative free cash flow can constrain investment capacity and heighten the consequences of funding delays.
Nasdaq Listing UncertaintyThe listing deficiency creates a structural risk to Kala Bio’s access to Nasdaq’s market infrastructure and investor base. A suspension or delisting could reduce trading liquidity and institutional participation, complicating future capital raising and weakening the company’s financial flexibility.
KALA BIO News
27F FAQ
What was KALA BIO’s price range in the past 12 months?
KALA BIO lowest stock price was €3.40 and its highest was €849.50 in the past 12 months.
What is KALA BIO’s market cap?
KALA BIO’s market cap is €9.38M.
When is KALA BIO’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were KALA BIO’s earnings last quarter?
Currently, no data Available
Is KALA BIO overvalued?
According to Wall Street analysts KALA BIO’s price is currently Overvalued.
Does KALA BIO pay dividends?
KALA BIO does not currently pay dividends.
What is KALA BIO’s EPS estimate?
KALA BIO’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KALA BIO have?
KALA BIO has 19,339,787 shares outstanding.
What happened to KALA BIO’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of KALA BIO?
Currently, no hedge funds are holding shares in DE:27F
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KALA BIO
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Technical Analysis
Daré Bioscience
―
Vyome Holdings
―
Citius Pharmaceuticals
―
Lexaria Bioscience
―
Exicure
―